{"id":"W2123811123","doi":"10.1093/annonc/mdn370","title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Institute for Health and Care Research; Roche","keywords":"FOLFOX; Medicine; Oxaliplatin; Folinic acid; Internal medicine; Capecitabine; Irinotecan; Colorectal cancer; FOLFIRINOX; Neutropenia; Oncology; FOLFIRI; Population; Clinical endpoint; Fluorouracil; Surgery; Chemotherapy; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003167934,0.002333801,0.00418616,0.0007712488,0.0005605168,0.001346215,0.001498362,0.002165632,0.006534304],"category_scores_gemma":[0.00221641,0.001007431,0.002391268,0.0007621247,0.001725389,0.001667782,0.000514014,0.003959871,0.0009422245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001329549,"about_ca_system_score_gemma":0.001525786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001734664,"about_ca_topic_score_gemma":0.003777356,"domain_scores_codex":[0.9989015,0.0006337966,0.00005699558,0.0001771107,0.00006579555,0.0001646654],"domain_scores_gemma":[0.9983256,0.0005578581,0.0003445,0.000159091,0.00007323547,0.000539641],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9840266,0.005501032,0.0002381677,0.0002316854,0.0005776518,0.00001771049,0.00003128653,0.0002147244,0.001472822,0.0000477573,0.0002804281,0.007360236],"study_design_scores_gemma":[0.9381227,0.06004042,0.000672038,0.00001194824,0.0003981629,0.00001436089,0.00001099211,0.0001667344,0.0003157428,0.00004162116,0.0001979404,0.000007372645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908075,0.003606124,0.0005625449,0.000570613,0.0005147719,0.001878722,0.0007440146,0.0001011361,0.001214724],"genre_scores_gemma":[0.9885076,0.002978269,0.001403048,0.0007531418,0.0005870581,0.001987434,0.0008328482,0.00003697151,0.002913598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006534304,"threshold_uncertainty_score":0.02185947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1341549568313934,"score_gpt":0.4386820001262048,"score_spread":0.3045270432948114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}